January 31, 2024
Trinity Biotech Announces Entry into a Letter of Intent with Bayer for a Joint Partnership to Launch a CGM Biosensor Device in China and India
DUBLIN, Ireland, January 31, 2024 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq: TRIB) (the “Company”) today announced that it has entered into a non-binding Letter of Intent with Bayer for the launch of a Continuous Glucose Monitoring (“CGM”) biosensor device in China and India.